PHBID (Neorich Biopharma Tech Co) EBIT per Share: $0.00 (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neorich Biopharma Tech Co EBIT per Share?

Neorich Biopharma Tech Co PHBID -44.44% EBIT per Share is $0.00 as of Jun. 2023.

Neorich Biopharma Tech Co's EBIT per Share for the three months ended in Jun. 2023 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Neorich Biopharma Tech Co's EBIT per Share or its related term are showing as below:

PHBID's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.55
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Neorich Biopharma Tech Co's EBIT for the three months ended in Jun. 2023 was $-0.14 Mil.

Neorich Biopharma Tech Co  (OTCPK:PHBID) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Neorich Biopharma Tech Co EBIT per Share Related Terms

Neorich Biopharma Tech Co EBIT per Share Historical Data

* Premium members only.

The historical data trend for Neorich Biopharma Tech Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neorich Biopharma Tech Co EBIT per Share Chart

Neorich Biopharma Tech Co Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
EBIT per Share
Get a 7-Day Free Trial -0.04 -0.01 -0.02 -0.01 -0.00

Neorich Biopharma Tech Co Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neorich Biopharma Tech Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Neorich Biopharma Tech Co's EBIT per Share for the fiscal year that ended in Sep. 2022 is calculated as

EBIT per Share(A: Sep. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.828/403.733
=-0.00

Neorich Biopharma Tech Co's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

EBIT per Share(Q: Jun. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.143/445.095
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $0.00 mean?
Neorich Biopharma Tech Co (PHBID) has a EBIT per Share of $0.00 as of Jun. 2023. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Neorich Biopharma Tech Co and its competitors.
Is Neorich Biopharma Tech Co's EBIT per Share too high?
Neorich Biopharma Tech Co's current EBIT per Share is $0.00.
How does Neorich Biopharma Tech Co's EBIT per Share compare to DVLP and CSTF?
Neorich Biopharma Tech Co's EBIT per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. The industry median EBIT per Share is 7.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.55, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Neorich Biopharma Tech Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neorich Biopharma Tech Co's current EBIT per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neorich Biopharma Tech Co stock overvalued right now?
Neorich Biopharma Tech Co (PHBID) has a current EBIT per Share of $0.00. The current EBIT per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Neorich Biopharma Tech Co (PHBID), the current EBIT per Share is $0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neorich Biopharma Tech Co Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.